Breast cancer

Score 6.5 = 6.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 4 of 4 trials are Phase 2+.

• Ph2NCT05076682 · Fudan University · Reverse Triple Negative Immune Resistant Breast Cancer
• Ph3NCT07432178 · Fudan University · CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）
• Ph2NCT07419880 · Fudan University · Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
• Ph2NCT04734262 · Fudan University · A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Score 5.6 = 5.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 6 of 6 trials are Phase 2+.

• Ph2NCT05328440 · Henan Cancer Hospital · Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
• Ph2NCT05296577 · Henan Cancer Hospital · Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
• Ph1/Ph2NCT05335473 · Henan Cancer Hospital · Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
• Ph2NCT07125950 · Henan Cancer Hospital · SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
• Ph2NCT06598046 · Henan Cancer Hospital · A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
• Ph3NCT04400695 · RemeGen Co., Ltd. · A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Score 5.1 = 5.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07112053 · University of Washington · A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
• Ph2NCT07721259 · University of Washington · A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

Score 5 = 5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT07578116 · SWOG Cancer Research Network · Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
• Ph2NCT06923527 · Yale University · Circulating Tumor DNA

Score 5 = 3 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 1 of 1 trials are Phase 2+.

• ESMO 2026 1RO (rapid oral) · Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy

• Ph2NCT07862751 · Emory University · US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy

Score 4.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 2 of 2 trials are Phase 2+.

• ESMO 2026 LBA15 (late breaking) · Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

• Ph1/Ph2NCT07208149 · Shenzhen Majory Biotechnology Co., Ltd. · A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
• Ph3NCT04400695 · RemeGen Co., Ltd. · A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Score 4.6 = 4.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT06917313 · Yale University · FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
• Ph3NCT05379153 · Alliance for Clinical Trials in Oncology · Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

Score 4.2 = 4.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07918989 · Memorial Sloan Kettering Cancer Center · A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After Mastectomy
• Ph3NCT05856773 · Proton Collaborative Group · Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

Score 4 = 4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT06144944 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
• Ph2NCT07796880 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Score 3.3 = 3.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07643428 · Medical College of Wisconsin · Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors
• Ph2NCT04243616 · Medical College of Wisconsin · Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

Score 3.3 = 3.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT07892274 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
• Ph3NCT04400695 · RemeGen Co., Ltd. · A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Score 3.2 = 3.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT05969860 · Mayo Clinic · At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
• Ph2NCT07285044 · Mayo Clinic · The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT06680596 · UNICANCER · Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
• Ph2NCT05625087 · UNICANCER · Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07743190 · Medical University of South Carolina · A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07619365 · Washington University School of Medicine · Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT04715542 · University of Bern · Stibium Metallicum Praeparatum D6 Versus Placebo in the Reduction of Paclitaxel-induced Peripheral Neurotoxicity

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07897409 · Universiti Sains Malaysia · The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07883512 · Virginia Commonwealth University · EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07914309 · Washington University School of Medicine · Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07706179 · University of Wisconsin, Madison · Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07899632 · Medsyn Biopharma, LLC · A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07857486 · Institut Paoli-Calmettes · Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07898943 · University Hospital, Clermont-Ferrand · Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority Study of Placebo vs Cefazolin

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07897409 · Universiti Sains Malaysia · The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07897409 · Universiti Sains Malaysia · The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07897409 · Universiti Sains Malaysia · The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07217990 · Ohio State University Comprehensive Cancer Center · Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07909889 · Aarhus University Hospital · Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07909408 · NYU Langone Health · Psilocybin FCR Early-Stage Breast Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07893730 · University College Cork · Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
• Ph2NCT01937117 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07654257 · Virginia Commonwealth University · Single FrAction Interstitial BreaSt BracHytherApy

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07848984 · Second Affiliated Hospital, Zhejiang University, School of Medicine · Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07643584 · University of Kansas Medical Center · De-Escalation of Axillary Management in Advanced Nodal Disease

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07410169 · Guangdong Provincial People's Hospital · Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07825454 · Indiana University · Pilot Study of Hydroxychloroquine for the Treatment of AIMSS

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07866430 · Montefiore Medical Center · De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer

Score 2.8 = 0.8 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 1 of 1 trials are Phase 2+.

• ESMO 2026 1768RO (rapid oral) · Radiation therapy followed by intrathecal (IT) trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal metastasis: Results from a phase II multi-institutional study, (INSPIRE-LM)

• Ph2NCT05528133 · H. Lee Moffitt Cancer Center and Research Institute · Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07826052 · Fudan University · Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07661927 · UNICANCER · Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07661927 · UNICANCER · Skipping Hormone Therapy in Low-Risk Early Breast Cancer